In the latest special edition of the podcast, we’re joined by Deborah Aitken, senior industry analyst at Bloomberg Intelligence for global luxury goods, beauty and personal care. Deborah talks us through the global recovery in the luxury industry, the impact of the Middle East conflict on spending and China’s importance to the comeback. Our special guest discusses valuations across the sector. Deborah gives us her take on trends within the high-end watch market. She also highlights the luxury names appealing to the important Gen Z consumer. Finally, our guest lends her view on developments at Coach-owner Tapestry (NYSE:TPR). She also…

Shares in Gattaca (LON:GATC) gained ground after the recruitment firm focused on the technology and engineering markets announced forecast-beating FY26 profits. Despite prevailing macroeconomic uncertainties, Gattaca insisted it is ‘well positioned with the demand for specialist skills and services remaining resilient’. As a result, the Fareham-based firm is confident it can deliver ‘further improvement in pre-tax profits in FY27’. Profits ahead of previous guidance Gattaca is an AIM-listed business whose brands include STEM skills expert Matchtech, cybersecurity recruiter Infosec People and Gattaca Projects. For the year to July 2026, Gattaca now expects to deliver underlying pre-tax profits of roughly £6.1…

In the latest Sharesify podcast, the gang discuss a hectic week for markets, a blockbuster IPO and looming results from retail heavyweights. Tech guru Steven brings us up-to-speed with updates from Applied Materials (NASDAQ:AMAT) and Cisco (NASDAQ:CSCO). He also provides a deep dive analysis of Anthropic. Its IPO could become one of the most important stock market events of 2026. James tells us why investment trust JPMorgan Claverhouse (LON:JCH) remains positive on the prospects for the UK market. He also discusses forecast-beating results from casino operator Rank (LON:RNK) and explains why luxury firm Tapestry (NYSE:TPR) fell out of fashion. Ian…

Affordable luxury goods group Tapestry (NYSE:TPR) delivered (13 August) forecast-beating Q4 earnings driven by margin expansion and double-digit sales growth at core brand Coach. The New York-based company’s sales grew in North America, China and Europe as the firm continued to bag market share. Share price: $128.39 (-16.5%)Market cap: $26bnPE FY27: 16.7Yield FY27: 1.4% So why did shares in Tapestry tumble 16.5% to $128.4 in after-hours trading on Wall Street? Well, FY27 guidance for sluggish sales growth disappointed investors. As did the protracted turnaround at Kate Spade New York, a brand Tapestry is struggling to revive. Tapestry weaves forecast-beating results…

Shares in Rank (LON:RNK) rose after the gaming and entertainment group reported forecast-beating FY26 profits and flagged a ‘good start’ to FY27. The Grosvenor Casinos and Mecca Bingo brands owner also reiterated its medium-term ambition to deliver underlying operating profits of at least £100 million. Income-hungry investors welcomed a 35% hike in the total dividend to 3.5p. This underscored management’s confidence in Rank’s improving cash generation and growth prospects. Rank generates growth across the board For the year to June 2026, Rank delivered a 21% rise in underlying operating profits to £78.6 million. That was ahead of recently-upgraded guidance. Like-for-like…

Investment trust JPMorgan Claverhouse (LON:JCH) lagged the benchmark in the six months to June 2026. Weakness in Serco (LON:SRP), Dunelm (LON:DNLM) and ICG (LON:ICG) impacted the fund’s relative performance. However, the UK equity income trust’s long-term track record of outperformance remains intact. And its managers are positive on the prospects for the UK market, insisting the opportunity set ‘remains compelling’. To learn more about JPMorgan Claverhouse, watch our Sharesify Podcast special featuring co-manager Anthony Lynch. Lagging the benchmark JPMorgan Claverhouse delivered a net asset value (NAV) total return of 6.6% for H1, underperforming the 7.2% rise in the FTSE All-Share Index. Relative…

Shares in Eco Animal Health (LON:EAH) rallied after the veterinary products specialist in-licensed a late-stage sheep toxoplasmosis vaccine from French biotech Vaxinano. Toxoplasmosis is a major cause of reproductive losses in sheep and other species. The vaccine candidate targets reproductive failure caused by Toxoplasma gondii. This is a major cause of abortions, stillbirths and weak lambs that can inflict significant losses on farmers. Investors are clearly excited by this licence, which strengthens AIM-listed Eco’s growing preventative medicines pipeline. The licence covers all important sheep rearing markets worldwide and the technology has patent protection too. Flocking to Eco Animal Health Eco…

In the latest episode of the Sharesify podcast, the guys discuss everything from high-flying markets to US tech and affordable luxury firm Tapestry (NYSE:TPR). Our tech expert Steven tells us why AI cloud platform CoreWeave (NASDAQ:CRWV) delivered the kind of quarter bulls wanted to see. James updates the audience on the latest from Omaha, where new Berkshire Hathaway (NYSE:BRK.B) boss Greg Abel has finally begun to deploy the conglomerate’s mammoth cash hoard. He also explains how Aberdeen Asia Focus (LON:AAS) passed a key five-year performance test. Markets guru Ian breaks down the recent upwards move in gold. He also tells us why shares…

Biotech’s fundraising and M&A bonanza continues to boost the specialist funds invested in this exciting growth industry. One healthcare trust benefiting from the boom is RTW Biotech Opportunities (LON:RTW). The London-listed fund has announced that private portfolio holding Avere Therapeutics is to merge with publicly-listed NextCure (NASDAQ:NXTC). Avere is the fourth private portfolio company RTW Bio has brought to the public markets by way of a reverse merger in 2026. The other three firms are Yarrow Bioscience (NASDAQ:YARW), Obsidian Therapeutics and Serapha Bio. RTW Biotech delivers fourth reverse merger The all-share reverse merger is expected to complete by year-end. And…

Investment trust Aberdeen Asia Focus (LON:AAS) beat its benchmark by 29.4% over the five years to 31 July 2026. As a result, the Asian small caps-focused fund passed a performance test that would otherwise have triggered a tender offer. A tender offer is a formal proposal by an investment trust to buy back a specific percentage of its own shares from shareholders at a set price, usually close to net asset value (NAV). It provides an exit route for investors when poor performance persists or the shares trade at a wide NAV discount. Aberdeen Asia Focus uncovers hidden gems Aberdeen…